Here’s what you should know.
1. Valeant was seeking to sell Salix for $10 billion, but quibbles over the price led to the deal’s ultimate demise.
2. Valeant could still sell the unit in the future. Neither Valeant nor Takeda commented on the deal to Bloomberg.
3. On the news, Valeant shares dropped 8 percent to $15.79. Takeda shares rose .3 percent to 4,701 yen.
4. Valeant has $30 billion in debt it has to pay down.
5. Valeant acquired Salix in 2015 for $11.1 billion.
6. Valeant announced on Nov. 29, 2016 that it would boost its sales force for two Salix products, Xifaxan and Relistor.
More articles on gastroenterology/endoscopy:
Dr. Andrew Conn to moderate IBD panels & more — 3 GI physicians in the headlines
Despite companywide losses, Allergan’s GI business is booming: 3 key notes
Vivelix enters into agreement with Idera over rights to develop and market GI drug: 4 notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
